CredoScientia - Bibliothèque

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.

BACKGROUND: Conversion therapy with hepatic arterial infusion chemotherapy (HAIC) combined with bevacizumab and sintilimab has shown promise for unresectable hepatocellular carcinoma (uHCC). However, …

Thérapies de Conversion

Liu, C. F., Zhao, X. H., Zhu, S. B., Yu, H. P., Xing, W. G., & Li, H. K. (2025). Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.. Front Immunol, 16, 1644570. https://doi.org/10.3389/fimmu.2025.1644570

01/01/2025 Lire →

Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.

BACKGROUND: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular c…

Thérapies de Conversion

Jin, Z., Li, X., Lv, L., Zhang, B., Ma, X., Chen, S., You, J., Wu, X., Wang, L., Liu, X., Wang, F., Chen, X., Yu, L., Zhang, S., & Zhang, L. (2025). Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.. J Hepatocell Carcinoma, 12, 1921-1941. https://doi.org/10.2147/JHC.S523476

01/01/2025 Lire →

A Novel Quadruple Conversion Therapy: Converting Initially Unresectable Hepatocellular Carcinoma to Resectable with pTAE-HAIC, Tyrosine Kinase Inhibitors, and Anti-PD-1 Antibodies.

PURPOSE: The aim of this study was to evaluate the potential of partial transcatheter arterial embolization (pTAE)-hepatic artery infusion chemotherapy (HAIC) in combination with tyrosine kinase inhib…

Thérapies de Conversion

Xiao, J., Li, Q., Zheng, W., Liao, K., Yu, Q., Huang, R., & Zhou, R. (2025). A Novel Quadruple Conversion Therapy: Converting Initially Unresectable Hepatocellular Carcinoma to Resectable with pTAE-HAIC, Tyrosine Kinase Inhibitors, and Anti-PD-1 Antibodies.. J Hepatocell Carcinoma, 12, 1807-1819. https://doi.org/10.2147/JHC.S523755

01/01/2025 Lire →

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV HER2-positive gastric cancer.

BACKGROUND: Whether the addition of trastuzumab to chemo(immuno)therapy for the preoperative treatment of patients with potentially resectable HER2-positive gastric cancer has clinical benefits remain…

Thérapies de Conversion

Zhang, X., Tian, Y., Wang, H., Song, S., Chen, Y., Liu, N., Zhang, C., Huang, X., Jiang, H., & Hou, H. (2025). Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV HER2-positive gastric cancer.. Front Immunol, 16, 1624943. https://doi.org/10.3389/fimmu.2025.1624943

01/01/2025 Lire →

Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.

OBJECTIVE: This study aimed to investigate hepatitis B virus (HBV) reactivation and its impact on postoperative survival in patients with HBV-related hepatocellular carcinoma (HCC) who underwent conve…

Thérapies de Conversion

Xu, S., Pang, Q., Wei, M., Liu, D., Yuan, D., Bai, T., Wang, X., Tang, Z., & Wu, F. (2025). Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.. Front Cell Infect Microbiol, 15, 1598193. https://doi.org/10.3389/fcimb.2025.1598193

01/01/2025 Lire →

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.

BACKGROUND: Transarterial chemoembolization (TACE) combined with Lenvatinib plus programmed death-1 inhibitor (PD-1 inhibitor) is recommended for unresectable hepatocellular carcinoma (uHCC), and it h…

Thérapies de Conversion

Lu, C., Liu, R., Zhang, Y., Luo, J., Luo, C., Jiang, Z., Huang, M., Qiu, C., & Chen, J. (2025). TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.. J Hepatocell Carcinoma, 12, 1527-1540. https://doi.org/10.2147/JHC.S517855

01/01/2025 Lire →

A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review.

Brain metastases occur in 40% of advanced NSCLC patients, with poorer prognosis in squamous subtypes. Immune checkpoint inhibitors (ICIs) combined with chemotherapy have revolutionized treatment, yet …

Thérapies de Conversion

Xu, X., & Ma, Z. (2025). A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review.. Front Immunol, 16, 1601125. https://doi.org/10.3389/fimmu.2025.1601125

01/01/2025 Lire →

Advancing human rights, health equity, and equitable health policy with LGBTQ+ people: An American Academy of Nursing consensus paper.

Health disparities among LGBTQ+ people arise from sociocultural contexts of gender oppression. Complex historical, legal, and policy landscapes perpetuate inequities through discriminatory legislation…

Thérapies de Conversion

Phillips, J. C., Cornelius, J. B., Neira, P. M., Hein, L., Ducar, D., Rose, C. D., Rosa, W. E., Ballout, S., Nagel, D. A., Millender, E. I. F., Neft, M. W., Jablonski, R. A., Murray, T. A., Stamps, D. C., Brous, E., & Keepnews, D. M. (2025). Advancing human rights, health equity, and equitable health policy with LGBTQ+ people: An American Academy of Nursing consensus paper.. Nurs Outlook, 73(5), 102496. https://doi.org/10.1016/j.outlook.2025.102496

01/01/2025 Lire →

Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

[This corrects the article DOI: 10.3389/fimmu.2025.1451965.].

Thérapies de Conversion

Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1647890. https://doi.org/10.3389/fimmu.2025.1647890

01/01/2025 Lire →

Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

BACKGROUND AND AIMS: Most Hepatocellular carcinoma (HCC) diagnoses occur at advanced stages precluding radical surgical resections. Conversion therapy offers a viable chance for patients with unresect…

Thérapies de Conversion

Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1451965. https://doi.org/10.3389/fimmu.2025.1451965

01/01/2025 Lire →

Comparison of survival benefit and safety profile between lenvatinib and donafenib as conversion therapy in patients with hepatocellular carcinoma.

OBJECTIVE: To compare the survival benefit and safety profiles between lenvatinib and donafenib when used as conversion therapies for patients with hepatocellular carcinoma (HCC) at the China National…

Thérapies de Conversion

Hou, Y., Gao, Z., Han, Y., Liu, C., Su, X., & Zhang, D. (2025). Comparison of survival benefit and safety profile between lenvatinib and donafenib as conversion therapy in patients with hepatocellular carcinoma.. Am J Transl Res, 17(5), 3496-3504. https://doi.org/10.62347/PBLA2928

01/01/2025 Lire →

Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report.

Cases with massive (diameter ≥10 cm) hepatocellular carcinomas (HCCs) are uncommon and typically have poor outcomes; however, conversion therapy offers a beacon of hope for remission in patients with …

Thérapies de Conversion

Zhang, X., Zhang, L., Zhao, S., Dai, L., Li, H., Wu, X., Yan, H., Lin, R., & Zhu, K. (2025). Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report.. Front Immunol, 16, 1529016. https://doi.org/10.3389/fimmu.2025.1529016

01/01/2025 Lire →